Complaints Outcomes

Search

Search Results

Search Again
Pharmacist Registrant 26 (Nov 15, 2021)

Pharmacist registrant 26 has satisfied the terms of a Consent Agreement reached with the Inquiry Committee on June 4, 2017. Limits and conditions on the pharmacist registrant’s registration as a pharmacist have now been removed by the Inquiry Committee. The pharmacist registrant’s name has been withheld pursuant to 39.3(4) of the Health Professions Act.


July 10, 2020 
(November 15, 2021 - Registration Suspended) 

The Inquiry Committee, pursuant to section 32.2(4)(b)(ii) of the Health Professions Act, has reached an Agreement with the pharmacist registrant to voluntarily suspend their registration as a pharmacist effective November 15, 2021. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant’s name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.


September 3, 2018
(July 10, 2020 - Limits and Conditions Removed)

The Inquiry Committee, pursuant to section 36(1) of the Health Professions Act, has reached an Agreement with the pharmacist registrant to further amend one of the terms in the Agreement of June 4, 2017. The Registrant can now work in a pharmacy where narcotic/controlled substances and Z-group drugs are counted and reconciled on a monthly basis.


January 17, 2018
(September 3, 2018 - Limits and Conditions Updated)

The Inquiry Committee, pursuant to section 36(1) of the Health Professions Act, has reached an Agreement with the pharmacist registrant to amend one of the terms in the Agreement of June 4, 2017. The pharmacist registrant can now work in a pharmacy where narcotic/controlled substances and Z-group drugs are counted and reconciled on a biweekly basis.


June 4, 2017
(January 17, 2018 - Limits and conditions updated)

The Inquiry Committee, pursuant to section 36(1) of the Health Professions Act, has reached a new revised Agreement with the pharmacist registrant whereby the Registrant consented to undertakings that include, but are not limited to:

  1. Complying with all terms of the Registrant’s monitoring program for a minimum of three additional years;

  2. Continuing counselling for one year from the date after Registrant had returned to work;

  3. Informing all managers and employers with whom Registrant gains employment of registrant’s medical condition and the limits and conditions on Registrant’s registration pursuant to the Agreement;

  4. Ensuring that all managers and employers with whom Registrant gains employment submits a written statement to the College declaring their awareness of Registrant’s medical condition and the agreement, and how they will accommodate and supervise Registrant working in pharmacy;

  5. Working in a pharmacy where narcotic/controlled substances and Z-group drugs are counted and reconciled on a weekly basis;

  6. Working a maximum number of hours and shifts per week for the first three months after signing the Agreement;

  7. Informing pharmacy manager of all wastages and breakages of narcotic, controlled, opioid and sedative drugs that the Registrant has to dispose of or deal with;

  8. Not conducting drug counts and/or conduct medication reconciliation for any narcotic/controlled substances or Z-group drugs;

  9. The Registrant will be restricted from acting in the following roles:

    1. an owner or manager of a pharmacy;
    2. a director of a corporation that owns a pharmacy; and
    3. a preceptor;

     

  10. The Registrant will notify the College regarding any of the following changes:

    1. changes in places of employment as a pharmacist;
    2. changes in residential address and phone number; and
    3. changes in medical provider;

     

The Agreement will remain in place for a minimum of four years or until such time as the Registrant’s physician states otherwise. The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant. The Inquiry Committee is satisfied that the undertakings will protect the public.


January 3, 2017
(June 4, 2017 – Limits and conditions updated)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended indefinitely on May 16, 2016. Pursuant to section 36 of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings involving regular monitoring for fitness to practice pharmacy. The undertakings include, but are not limited to:

  1. That the Registrant will comply with all terms of Registrant’s monitoring program with the company currently involved in registrant’s care and remain on this program for a minimum of three (3) years from the day Registrant returns to active employment as a pharmacist;

  2. That Registrant will continue counselling for one (1) year after Registrant returns to work;

  3. That Registrant will inform all managers and employers with whom Registrant gains employment of registrant’s medical condition and the limits and conditions on Registrant’s registration pursuant to this agreement;

  4. That Registrant will ensure that all managers and employers with whom Registrant gains employment submit a written statement to the College within 48 hours of securing employment, declaring their awareness of Registrant’s medical condition and the agreement, how they will accommodate and supervise the Registrant working in the pharmacy, and that they will submit a weekly narcotic count for a minimum of three (3) months to the College or advise the College if any narcotic count concerns arise;

  5. That after returning to work in a pharmacy setting, Registrant will provide work sign-in sheets on a monthly basis;

  6. That Registrant will not work alone after returning to work in a pharmacy setting and that there must be overlapping shifts of at least one registrant during Registrant’s work shift for a minimum of the first six (6) months that Registrant returns to work;

  7. That after returning to work in a pharmacy setting, Registrant will not be allowed to dispense narcotics;

  8. That after returning to work in a pharmacy setting, Registrant will not handle or physically prepare prescriptions for narcotic, controlled, opioid and sedative drugs, including but not limited to Benzodiazepine, Dextroamphetamine and testosterone products and any Z-Group drugs;

  9. That after returning to work in a pharmacy setting, for the first six (6) months, Registrant will not be allowed to dispense Controlled Substances ie. Benzodiazepine, Dextroamphetamine and testosterone products and any Z-Group drugs (which are not considered Controlled Substances);

  10. That after returning to work in a pharmacy setting, Registrant will not be allowed to do narcotic or controlled substances or Z-Group drug counts;

  11. That after returning to work in a pharmacy setting, Registrant will not dispose or deal with wastage or breakage of or otherwise handle any narcotic, controlled, opioid and sedative drugs, including but not limited to Benzodiazepine, Dextroamphetamine and testosterone products and any Z-Group drugs;

  12. That Registrant will not have access to the narcotic-safe or physically process and/or otherwise prepare any prescriptions that require access to the narcotic safe;

  13. That Registrant will not be involved in any way with ordering supplies of narcotic medications;

  14. That Registrant will be restricted from acting in the following roles in Registrant’s practice:

    1. an owner or manager of a pharmacy;
    2. a director of a corporation that owns a pharmacy; and
    3. a preceptor;

     

  15. That Registrant will notify the College within 48 hours of such a change, in writing or via e-mail, of:

    1. all changes in places of employment as a pharmacist;
    2. all changes in residential address and phone number; and
    3. all changes in medical provider;

The Agreement will remain in place for a minimum of five years from the date of execution of the Agreement. The Registrant will be assessed by the treating physician after six (6) months upon return to active employment to determine whether or not any of the above limits or conditions should be removed. The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public.


May 16, 2016
(January 3, 2017 – Registration Reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an Agreement with pharmacist registrant to suspend registration as a pharmacist effective May 16, 2016. The agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The registrant's name has been withheld, pursuant to 39.3(4) of the Health Professions Act.

Pharmacist Registrant 46 (Nov 10, 2021)

The Inquiry Committee has changed the pharmacist registrant’s status to “Full Pharmacist – Active” which had previously been “Full Pharmacist – Suspended” for an indefinite period on November 20 2020. Pursuant to section 36(1) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the registrant consented to terms that include, but not limited to, the following:

  • To comply with all treatment plans as recommended by their medical providers;
     
  • To comply with all terms of the Relapse Prevention Agreement for a duration of three years;
     
  • Ensuring that all managers and employers with whom they gain employment submit a written statement to the College declaring their awareness of their medical condition and the agreement;
    • To be restricted from acting in the following roles:
    • owner (direct or indirect) or manager of a pharmacy;
    • director of a corporation that owns a pharmacy; and
    • preceptor;
  • To authorize and direct any and all caregivers, treating physician(s), and/or institution(s) to furnish the College with a written report and any and all information that relates to their health, including a diagnosis, prognosis, status of recovery and/or treatment plan pertaining to their health condition and recovery, when and if necessary for the College to obtain such information;
     
  • To authorize the College to provide their treating physician(s) and any practitioner involved in their care with any information and documentation necessary for an independent medical assessment as well as monitoring and/or follow-up therapy, as necessary.

The Inquiry Committee considers the Agreement necessary to protect the public. The registrant’s name has been withheld pursuant to section 39.3(4) of the Health Professions Act.


November 20, 2020
(November 10, 2021 - Suspension Ended)

The Inquiry Committee, pursuant to section 32.2(4)(b)(ii) of the Health Professions Act, has reached an Agreement with the pharmacist registrant to voluntarily suspend their registration as a pharmacist effective November 20, 2020. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant’s name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.

Pharmacist Registrant 48 (Nov 4, 2021)

The Inquiry Committee has changed the pharmacist registrant’s status to “Full Pharmacist – Active” which had previously been “Full Pharmacist – Suspended” for an indefinite period on December 18, 2020. Pursuant to section 36(1) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the registrant whereby the registrant consented to terms including, but not limited to, the following:

  • To adhere to all steps and comply with all treatment and recovery plans as recommended by their medical provider(s) and/or their most responsible physician(s);
  • To comply and complete all terms of the Relapse Prevention Agreement for a duration of three years and with a graduated return to work over a minimum of seven weeks; and 
  • To authorize and direct any and all caregivers and treating physicians to provide the College with a report and information that relates to the registrant’s health, recovery, and/or treatment plan pertaining to any health condition what could materially impair the registrant’s performance and/or fitness to practice pharmacy.

The Inquiry Committee considers the Agreement necessary to protect the public. The registrant’s name has been withheld pursuant to section 39.3(4) of the Health Professions Act.


December 18, 2020
(November 4, 2021 - Suspension Ended)

The Inquiry Committee, pursuant to section 32.2(4)(b)(ii) of the Health Professions Act, has reached an Agreement with the pharmacist registrant to voluntarily suspend their registration as a pharmacist effective December 18, 2020. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant’s name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.

Seelaboyina, Bhanu Prasad (Sep 21, 2021)

The Inquiry Committee, pursuant to section 32.2(4)(b)(i) of the Health Professions Act, has reached an Agreement with pharmacist registrant Bhanu Prasad Seelaboyina (the “Registrant”) to impose limits and conditions on his practice, effective immediately, pending an investigation into his conduct. The Registrant has agreed to the following limits and conditions on his practice, which are in place until further notice:

  1. Until investigations into his conduct are complete and until approved by the Inquiry Committee to do so:
    1. To not act in the role of a pharmacy manager; and
    2. To not administer drugs or substances by injection and/or intranasal route; and
       
  2. To authorize the College to revoke his Drug Administration Certification, effective immediately. 

The Registrant has admitted to using the same syringe barrel for multiple patients while administering COVID-19 vaccinations between August 24, 2021 and August 26, 2021. This conduct occurred while he was in a leadership role as a pharmacy manager.

Due to the Registrant’s conduct and judgment in this case, the Inquiry Committee considered the above limits and conditions necessary to protect against further risk of harm to patients.

Pharmacist Registrant 6 (Sep 13, 2021)

The Inquiry Committee has approved to change pharmacist’s registration back to Active status after it had previously been suspended for an indefinite period on April 18, 2021. Pursuant to section 36(1) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the pharmacist registrant consented to terms including, but not limited to, the following:

  1. To comply with any and all treatment plans as recommended by their medical providers;
     
  2. To comply with any and all return to work plans as advised by their medical providers and/or employers;
     
  3. To voluntarily stop working as a pharmacist and self-report to the College in the event that their medical condition may hinder their performance and/or fitness to practice as a pharmacist;
     
  4. To authorize and direct any and all caregivers, treating physicians, and/or institution(s) to furnish the College with a written report and any and all information that relates to their health, including a diagnosis, prognosis, status of recovery and/or treatment plan pertaining to their health condition and recovery, when and if necessary for the College to obtain such information;
     
  5. The College may furnish their treating physician(s) and any practitioner involved in their care with any information and documentation necessary for an independent medical assessment as well as monitoring and/or follow-up therapy, as necessary.

The pharmacist registrant’s name has been withheld pursuant to section 39.3(4) and (6) of the Health Professions Act.


December 8, 2020
(August 9, 2021 - Registration Reinstated)

The Inquiry Committee, pursuant to section 32.3(3)(b)(ii) of the Health Professions Act, has reached an Agreement with the pharmacist registrant to voluntarily suspend their registration as a pharmacist effective December 8, 2020. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant’s name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.


April 18, 2021
(September 13, 2021 - Registration Resinstated)

The Inquiry Committee, pursuant to section 32.2(4)(b)(ii) of the Health Professions Act, has reached an Agreement with the pharmacist registrant to voluntarily suspend their registration as a pharmacist effective April 18, 2021. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant’s name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.


February 20, 2015
(April 18, 2021 - Registration suspended)

Pharmacist Registrant 6 has satisfied the terms of an agreement reached with the Inquiry Committee dated October 3, 2010. Limits and conditions on pharmacist registrant’s registration as a pharmacist have now been removed. The pharmacist registrant’s name has been withheld pursuant to 39.3(4) of the Health Professions Act.


October 3, 2010
(February 20, 2015 - Limits and conditions removed)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with pharmacist registrant to place limits and/or conditions on his registration as a pharmacist effective October 3, 2010. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act

Pharmacist Registrant 47 (Aug 9, 2021)

The Inquiry Committee has approved to change pharmacist’s registration back to Active status after it had previously been suspended for an indefinite period on December 8, 2020. Pursuant to section 36 of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the pharmacist registrant consented to terms including, but not limited to, the following:

  1. To comply with any and all treatment plans as recommended by their medical providers.
     
  2. To comply with any and all return to work plans as advised by their medical providers and/or employers.
     
  3. To voluntarily stop working as a pharmacist and self-report to the College in the event that their  medical condition may hinder their performance and/or fitness to practice as a pharmacist.
     
  4. To authorize and direct any and all caregivers, treating physicians, and/or institution(s) to furnish the College with a written report and any and all information that relates to their health, including a diagnosis, prognosis, status of recovery and/or treatment plan pertaining to their health condition and recovery, when and if necessary for the College to obtain such information.

The pharmacist registrant’s name has been withheld pursuant to section 39.3(4) and (6) of the Health Professions Act.


December 8, 2020
(August 9, 2021 - Registration Reinstated)

The Inquiry Committee, pursuant to section 32.3(3)(b)(ii) of the Health Professions Act, has reached an Agreement with the pharmacist registrant to voluntarily suspend their registration as a pharmacist effective December 8, 2020. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant’s name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.

Pharmacist Registrant 50 (Aug 3, 2021)

The Inquiry Committee, pursuant to s. 32.2(4)(b)(ii) of the Health Professions Act, has reached an agreement with the pharmacist registrant to voluntarily suspend the registration as a pharmacist effective August 3, 2021. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.

Odijie, Wilson Akhahon (Jul 27, 2021)
  1. Nature of Action: The Inquiry Committee of the College of Pharmacists of British Columbia (“CPBC”) conducted an investigation into the practice of Wilson Akhahon Odijie (the “Registrant”), pursuant to section 33(4) of the Health Professions Act, R.S.B.C. 1996, c. 183.

    The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the  Health Professions Act.

  2. Effective date: July 27, 2021

  3. Name of registrant: Wilson Akhahon Odijie

  4. Location of Practice: Dawson Creek, BC

  5. Admissions and acknowledgements:

    The Registrant has admitted and/or acknowledged the following:

    Between May and June 2020, while he was the pharmacy manager and pharmacist, the Registrant sold an unregulated natural health product called Ankoro powder to patients at a BC licensed pharmacy.

    The Inquiry Committee considered that the Registrant’s actions, conduct, and statements in relation to the ethical standards contravened, included the following:

    1. The Registrant did not confirm with Health Canada that the Ankoro powder was regulated or available to purchase in Canada. The Registrant did not purchase the Ankoro powder from a Health Canada approved wholesaler or pharmacy approved distributers.
       
    2. The Registrant did not use evidence-based information to determine if the Ankoro powder was safe or effective. The Registrant did not provide evidence-based information for the patients in this matter to make an informed decision about the purchase, use, and side effects of Ankoro powder.
       
    3. The Registrant sold the Ankoro powder as a regulated healthcare professional in a licensed pharmacy to four pharmacy patients.
  1. Disposition:

    The Registrant entered into a Consent Agreement with the Inquiry Committee of CPBC, wherein the Registrant consented to the following terms:

    1. To not be a pharmacy manager and preceptor for a period of two years commencing on July 27, 2021 until July 26, 2023;

    2. To successfully complete and pass an ethics course for healthcare professionals within six months;

    3. To read and/or successfully complete courses on:

      • Decision making and documentation,

      • Pharmacy inventory,

      • Researching and critically appraising evidence and recognizing high-quality evidence-based literature, and

      • Health Canada’s policies and guidelines for purchasing and selling unscheduled, unregulated products to patients.

    4. To have a Letter of Reprimand placed on his registration record for two years.

  2. Rationale:

    The Inquiry Committee considered that by procuring, purchasing, and selling Ankoro powder without evidence-based information as a registered pharmacist at a licensed pharmacy, the Registrant exhibited poor judgement that could undermine patient trust in registrants and society’s trust in the pharmacy profession. As a pharmacist and as a professional, the Registrant is expected to act in a manner consistent with the HPA, Bylaws, Schedule A, Code of Ethics (“Code of Ethics”). His actions did not support his behaviour. The procurement and sale of an unapproved, unregulated product did not protect or promote the health and well-being of his patients. The Registrant’s overall conduct amounted to professional misconduct given the violations of the Code of Ethics Standards.

    The Inquiry Committee considered the Registrant’s conduct to be serious, and that the Registrant required remediation to come into compliance. Therefore, the Inquiry Committee considered the terms of the Consent Agreement necessary to protect the public, to prevent and deter the Registrant from similar issues occurring in his future practice, and to send a clear message of deterrence to the profession. 

Filipovic, Nemanja (Jul 16, 2021)
  1. Nature of Action: The Inquiry Committee of the College of Pharmacists of British Columbia (the “College”) conducted an investigation into the practice of now former registrant Nemanja Filipovic (the “Former Registrant”), pursuant to section 33(4) of the Health Professions Act, R.S.B.C. 1996, c. 183.

    The Inquiry Committee and the Former Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the Health Professions Act.

  2. Effective date: July 16, 2021

  3. Name of registrant: Nemanja Filipovic

  4. Location of Practice: N/A

  5. Admissions and acknowledgements:

    Between January 2012 and June 2018, at two pharmacies, over 36,000 transactions for (non-narcotic) prescription medications, over-the-counter (“OTC”) and/or vitamin products were processed as either one-day or seven-day supplies on the PharmaNet records of 22 individuals. These 22 individuals were all either current or former employees of the two pharmacies, or family members of former employees of the two pharmacies.

    These transactions were processed contrary to the way in which medications were dispensed to the 22 individuals and there was no clinical indication for the medications to be processed and/or dispensed on a daily or weekly basis, or to be dispensed at all. Furthermore, over 17,000 of these transactions were also backdated, to make it appear on PharmaNet that the transactions were processed on certain dates when in fact they were not.

    At all material times, the Former Registrant was the director and owner of these two pharmacies.

    The Former Registrant admitted that as the director and owner of the two pharmacies, he had suggested to and enabled staff at the two pharmacies to process prescriptions in this manner in order to artificially inflate prescription counts in order to meet corporate targets. His actions enabled the inappropriate access and use of personal information and PharmaNet records, and caused PharmaNet records to be inaccurate.

  1. Disposition:

    The Former Registrant entered into a Consent Agreement with the College’s Inquiry Committee, wherein the Former Registrant consented to terms that included (but not limited to) the following:

    1. To pay a $30,000.00 fine;

    2. To have his registration as a pharmacist suspended for a total of 540 days, to commence upon his reinstatement to Full Pharmacist status;

    3. To not be a pharmacy manager, director, owner (direct or indirect), shareholder, and preceptor for pharmacy students for a period of five years from the date that his suspension ends;

    4. To complete and successfully pass the College’s Jurisprudence Exam within one year of reinstatement to Full Pharmacist status;

    5. To successfully complete and unconditionally pass an ethics course for healthcare professionals within one year of reinstatement to Full Pharmacist status; and

    6. To appear before the Inquiry Committee for a verbal reprimand after completing the above term.

  2. Rationale:

    The Inquiry Committee determined that in his role as the pharmacies’ owner and director, the Former Registrant was in contravention of legislation which required him to ensure that meeting quotas, targets, or similar measures did not compromise patient safety or compliance with the bylaws, Code of Ethics or standards of practice. His actions, which were motivated by personal gain, enabled and perpetuated the processing of over 36,000 inaccurate PharmaNet transactions and the backdating of over 17,000 transactions, placing the affected patients at risk of harm.

    The Former Registrant’s actions were considered serious contraventions of legislation involving his role as a pharmacy director and owner. He also contravened standards of the Code of Ethics involving protecting and promoting the well-being of patients, benefitting society, committing to personal and professional integrity, and participating in ethical business practices. The totality of his conduct amounted to significant professional misconduct, which warranted the remediation and sanctions referenced above.

    The Inquiry Committee considered the terms of the Consent Agreement necessary to protect the public, as well as send a clear message of deterrence to the profession. Inappropriate access and use of personal health information compromises the public’s trust in the pharmacy profession as a whole. At all times, registrants must uphold legislative requirements and ethical obligations to appropriately access, use and protect personal health information.

Pharmacist Registrant 9 (Jun 29, 2021)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached a new agreement with the pharmacist registrant, whereby the registrant consented to undertakings involving regular medical monitoring for fitness to practice pharmacy. The undertakings in the agreement include, but are not limited to the following:

  • Informing all managers and employers with whom the registrant gains employment of the registrant’s medical condition and the need to maintain vigilance with respect to recovery and the possibility of relapse, and the limits and conditions on registration pursuant to the agreement;
     
  • Ensuring that all managers and employers with whom the registrant gains employment submit a written statement to the College declaring awareness of the registrant’s medical condition and the agreement;
     
  • Being restricted from the following roles in practice:
    • Manager of a pharmacy;
    • Direct or indirect owner of a pharmacy; and
    • Preceptor for pharmacy students and/or international pharmacy graduates;
       
  • Notifying the College of:
    • all changes in places of employment as a pharmacist;
    • all changes in residential address and phone number; and
    • all changes in medical providers.

The name of the registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public.


March 22, 2021
(June 29, 2021 - Limits and Conditions Updated)

Pharmacist Registrant 9 has satisfied the terms of an agreement reached with the Inquiry Committee dated March 23, 2016. Limits and conditions on pharmacist registrant’s registration as a pharmacist have now been removed. The pharmacist registrant’s name has been withheld pursuant to 39.3(4) of the Health Professions Act.


March 23, 2016
(March 22, 2021 – Limits and conditions removed)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached a new agreement with the pharmacist registrant for an additional five year period until March 23, 2021, whereby the registrant consented to undertakings involving regular medical monitoring for fitness to practice pharmacy. The undertakings in the agreement include, but are not limited to the following:

  1. Informing all managers and employers with whom he gains employment of his medical condition and the need to maintain vigilance with respect to recovery and the possibility of relapse, and the limits and conditions on his registration pursuant to the agreement;

  2. Ensuring that all managers and employers with whom he gains employment submits a written statement to the College declaring their awareness of his medical condition and the agreement;

  3. Being restricted from the following roles in his practice:

    1. an owner or manager of a pharmacy;
    2. a director of a corporation that owns a pharmacy; and
    3. a preceptor.

     

  4. Notifying the College of:

    1. all changes in his places of employment as a pharmacist
    2. all changes in residential address and phone number; and
    3. all changes in medical providers

The name of the registrant has been withheld in accordance with section 39.3 (4) (a) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public.


August 6, 2015
(March 23, 2016 - Limits and Conditions Updated)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with the pharmacist registrant to remove the following undertakings:

  1. To return to work gradually, in accordance with the recommendations of his physician;
  2. To not work alone for a period of six months after returning to work in a pharmacy setting, meaning that he must never be the sole pharmacist in attendance at any time and that there must be another pharmacist in good standing working with him at all times;
  3. Not being involved in the dispensing, ordering, contact, destruction, counting or otherwise handling of opiate and benzodiazepine type medications.

The remainder of the undertakings are in effect until further notice.  The pharmacist registrant’s name has been withheld in accordance with section 39.3 (4) (a) of the Health Professions Act.


August 19, 2014
(August 6, 2015 – Partial undertakings removed)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with the pharmacist registrant whereby the registrant consented to undertakings involving regular monitoring for fitness to practice pharmacy. The undertakings include, but are not limited to:

  1. Routine and random medical monitoring;

  2. Informing all managers and employers with whom he gains employment of his medical condition and the need to maintain vigilance with respect to recovery and the possibility of relapse, and the limits and conditions on his registration pursuant to the agreement;

  3. Ensuring that all managers and employers with whom he gains employment submits a written statement to the College declaring their awareness of his medical condition and the agreement;

  4. To return to work gradually, in accordance with the recommendations of his physician;

  5. To not work alone for a period of six months after returning to work in a pharmacy setting, meaning that he must never be the sole pharmacist in attendance at any time and that there must be another pharmacist in good standing working with him at all times;

  6. Not being involved in the dispensing, ordering, contact, destruction, counting or otherwise handling of opiate and benzodiazepine type medications;

  7. Being restricted from the following roles in his practice:

    1. an owner or manager of a pharmacy;
    2. a director of a corporation that owns a pharmacy; and
    3. a preceptor.

     

  8. Notifying the College of:

    1. all changes in his places of employment as a pharmacist
    2. all changes in residential address and phone number; and
    3. all changes in medical provider.

The agreement will remain in place for a minimum of two years of continuous pharmacy practice. The name of the Registrant has been withheld in accordance with section 39.3 (4) (a) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public.


March 15, 2011
(August 19, 2014 – Registration reinstated)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with the pharmacist registrant to suspend his registration as a pharmacist effective March 15, 2011. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act

 

Pages